1. Home
  2. RCKY vs IFRX Comparison

RCKY vs IFRX Comparison

Compare RCKY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Brands Inc.

RCKY

Rocky Brands Inc.

N/A

Current Price

$46.31

Market Cap

352.5M

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$2.07

Market Cap

303.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RCKY
IFRX
Founded
1932
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
352.5M
303.4M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
RCKY
IFRX
Price
$46.31
$2.07
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$40.00
$6.25
AVG Volume (30 Days)
63.1K
879.9K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
1.71%
N/A
EPS Growth
94.74
N/A
EPS
1.99
N/A
Revenue
$270,408,000.00
N/A
Revenue This Year
$8.12
N/A
Revenue Next Year
$4.90
N/A
P/E Ratio
$23.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.30
$0.80
52 Week High
$53.01
$2.95

Technical Indicators

Market Signals
Indicator
RCKY
IFRX
Relative Strength Index (RSI) 51.16 58.65
Support Level $31.90 $0.83
Resistance Level $48.70 $2.94
Average True Range (ATR) 1.48 0.12
MACD -0.51 0.03
Stochastic Oscillator 18.51 73.58

Price Performance

Historical Comparison
RCKY
IFRX

About RCKY Rocky Brands Inc.

Rocky Brands Inc is a designer, manufacturer, and marketer of premium footwear and apparel under brands such as Muck, XTRATUF, Rocky, Durango, Georgia Boot, Lehigh, Ranger, and the licensed brand Michelin. The company operates through three segments, with the wholesale segment generating the majority of revenue through sales of footwear and accessories to sporting goods stores, outdoor specialty stores, online retailers, marine stores, independent retailers, mass merchants, retail uniform stores, and specialty safety shoe stores. The retail segment focuses on direct-to-consumer sales through e-commerce platforms and company-operated stores, while the contract manufacturing segment includes sales to the U.S. military, private label production, and sourcing arrangements for customers.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: